Nephropathy in Patients With Sickle Cell Disease


There are some diseases that give rise to diverse renal manifestations as does sickle cell disease

Full Title of Study: “Pattern of Sickle Cell Nephropathy in Patients With Sickle Cell Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: May 30, 2020

Detailed Description

Such involvement adversely affects virtually all major physiological processes in the kidney, and leads to complications that are common and chronic on the one hand (such as impaired urinary concentrating ability), and those that are rare and uniformly fatal on the other (such as renal medullary carcinoma) This steady adverse renal sequelae shortens the average lifespan of patients with SCD. Proteinuria and a reduced glomerular filtration rate are risk factors associated with increased mortality among those patients with approximately 16-18% of overall mortality in this patient group is due to kidney disease. Once end stage renal disease is reached, the mortality of patients who are on haemodialysis and have SCD is increased severalfold relative to the mortality of patients who are on haemodialysis but do not have SCD. Thus,although the average lifespan of patients with SCD has increased during recent decades owing to improved management of complications outside the kidney,kidney disease contributes substantially to the still increased mortality in SCD.


  • Other: patient with sickle cell disease
    • assess degree of renal affection in patientswith sickle cell disease attending Assuit university Children hospital by estimating some predictors of glomerular and tubular dysfunction.

Clinical Trial Outcome Measures

Primary Measures

  • sickle cell nephropathy in patient with sickle cell disease
    • Time Frame: one year
    • detection of renal impairment in patients with sickle cell disease by estamating gloerular and tubular dysfunction clinicaly and laboratory

Participating in This Clinical Trial

Inclusion Criteria

  • All patients with sickle cell anemia attending the unit will be included in the study. Exclusion Criteria:

  • patient with any underlaying systemic diseases other than sickle cell anaemia

Gender Eligibility: All

Minimum Age: 5 Months

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assiut University
  • Provider of Information About this Clinical Study
    • Principal Investigator: omnia talat hasan, assiut – Assiut University
  • Overall Official(s)
    • omnia talat hasan, Principal Investigator, assiut
  • Overall Contact(s)
    • fahim mohamed fahim, 01002500073,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.